TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of mild cognitive impairment due to Alzheimer's disease (MCI due to AD) by the patient's referring clinician per recent National Institutes of Aging-Alzheimer's Association criteria (Albert et al., 2011).~* A diagnosis of mild Alzheimer's disease by the patient's referring clinician per recent National Institutes of Aging-Alzheimer's Association criteria (McKhann et al., 2011).~* 50-90 years of age.~Exclusion Criteria:~* Younger than the age of 50 or older than the age of 90.~* Any self-reported history of substance abuse or alcohol abuse.~* Any self-reported history of prior head trauma (e.g., stroke, traumatic brain injury)~* Any prior self-reported history of significant depression or other mood disorder.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): In the Intervention Group, patients will receive an iPad with the Constant Therapy cognitive rehabilitation application. Patients in the Intervention Group will practice the memory tasks developed for the Constant Therapy application for a total of six months. On a weekly basis, a clinician and/or research assistant will check in with the patient to answer any questions or address any concerns the patient has with using the Constant Therapy application, or how to perform any of the memory tasks. At the end of six months, each individual in the Intervention Group is assessed with standard cognitive testing to determine if there was any change on overall cognition.
- Control Group (Type: ACTIVE_COMPARATOR): The Control Group will not receive any intervention. The Control Group will be given simple sets of puzzle booklets to practice over the 6 month period (e.g., word search puzzles, number and/or math puzzles). The Control Group will also receive standardized cognitive testing at the end of 6 months. Weekly check-ins by a clinician and/or research assistant will also occur in the Control Group. Every 4th patient recruited for the study will be assigned to the Control Group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. DBMD as determined by either a skeletal muscle biopsy demonstrating absence or lack of dystrophin, and/or genetic testing showing a mutation in the dystrophin gene predictive of DBMD, as well as a consistent physical examination~2. Male gender~3. Age greater than or equal to 18 years~4. Cardiac dysfunction with ejection fraction less than or equal to 50% as determined by echocardiogram, cardiac MRI, or multi-gated acquisition (MUGA) scan~5. On a stable dose of ACE-inhibitor or angiotensin receptor blocker (ARB) for at least 3 months; beta-adrenergic receptor blockers and glucocorticosteroids are not required but if used, a stable dose for at least 3 months is required.~6. Ability of the subject or legal guardian to provide informed consent~7. Ability to adhere with study follow-up~8. Willingness to abstain from food and alcohol for 8 hours prior to FMD~Exclusion Criteria:~1. Use of nitrates or alpha-adrenergic receptor blockers~2. Known intolerance or allergy to sildenafil, or a history of any severe allergic or anaphylactic reactions~3. Any medical or psychosocial condition, which, in the view of the study investigator, makes study participation inadvisable~4. Known hereditary retinal disorder such as retinitis pigmentosa~5. History of priapism or conditions that may predispose to priapism such as sickle cell anemia, multiple myeloma, or leukemia~6. Bleeding disorders~7. Active tobacco use~8. Chronic atrial fibrillation or frequent arrhythmia that would result in an irregular pulse~9. Factors that would preclude obtaining an MRI study - (e.g. implantable pacemaker or cardioverter-defibrillator; body habitus cannot fit into scanner)~10. Systolic blood pressure (SBP) less than 85 mmHg at baseline evaluation~11. Chronic kidney disease stages 4 and 5: GFR\< 30 mL/min/1.73 m2 as determined by serum cystatin C level and the equation eGFRcys = 76.7 x (serum cystatin C-1.18)~12. Current use of sildenafil.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Revatio (sildenafil) (Type: EXPERIMENTAL): This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
- Placebo (Type: OTHER): This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Early Screening and Intervention for Gestational Diabetes Mellitus on Pregnancy Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 20 years old~2. First prenatal visit before 14 weeks of GA~3. Deliver a singleton at medical centers, including National Taiwan University Hospital (NTUH), and NTUH, Hsinchu Branch.~Exclusion Criteria:~1. Diagnosed with preexisting diabetes~2. Twin or multiple births pregnancy~3. Current exposure to steroids~4. Cannot tolerate an OGTT

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Early-screen Group (Type: EXPERIMENTAL): The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). The time of early screening and intervention will be 6-8 weeks earlier than that of standard screening and intervention.
- Standard-screen Group (Type: ACTIVE_COMPARATOR): The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). The time of standard screening and intervention will be 6-8 weeks later than that of early screening and intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Esmolol on a Closed-Loop Anesthesia System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male patients scheduled for a general anesthesia~Exclusion Criteria:~* age lower than 18 years~* allergy to propofol, or to soja or to peanuts, or to sufentanil, to remifentanil, or to morphine, or to a myorelaxant or to an excipient,~* any other history of anaphylactic reaction,~* hypersensibility to sufentanil, or to remifentanil, or to other derivate of fentanyl,~* hypersensibility to esmolol or to an excipient,~* history of central nervous system disease,~* patients receiving a psychotropic treatment or an agonist-antagonist opiate,~* hypovolemic patients,~* patients receiving a cardio-vascular treatment,~* patients with a pacemaker,~* expected bleeding more than 20% of the blood volume,~* simultaneous general and loco-regional anesthesia,~* patients suffering from asthma, COPD, trouble of the heart rhythm or conduction, cardiac insufficiency, cardiogenogenic shock, Prinzmetal syndrome, pheochromocytoma,~* patients with a heart rate less than 50/min and/or an arterial hypotension,~* neurosurgical act or any other which precludes an adequate positioning of the bispectral electrode.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
- Esmolol (Type: EXPERIMENTAL): patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and esmolol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Armodafinil for Patients Starting Hepatitis C Virus Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HCV+ patients medically cleared for IFN/RBV treatment -HIV+ or HIV-~* Speaks English~* Able and willing to give informed consent~* Fecund women: use barrier method of contraception~Exclusion Criteria:~* Untreated and uncontrolled hypertension~* Left ventricular hypertrophy~* Currently taking stimulant medication~* Uncontrolled mental health problems including: MDD, suicidal or homicidal ideation, bipolar disorder, or schizophrenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Armodafinil (Type: EXPERIMENTAL): Active medication
- Sugar pill (Type: PLACEBO_COMPARATOR): Inactive pill, matched to look like active medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of the Swedish National Tobacco Quitline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Tobacco users calling the SNTQ to discuss his/her own tobacco behaviour.~* The client gives verbal consent to sign up for cessation support.~* The client return a registration form including a baseline questionnaire~Exclusion Criteria:~* Snuff cessation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Proactive service (Type: EXPERIMENTAL): Intervention: Tobacco cessation by telephone support. The structured treatment protocol is a mixture of motivational interviewing (MI), cognitive behaviour therapy, and pharmacological consultation. In the proactive service the callers to the quitline are offered a number of callbacks.
- Reactive service (Type: ACTIVE_COMPARATOR): Intervention: Tobacco cessation by telephone support. The structured treatment protocol is a mixture of motivational interviewing (MI), cognitive behaviour therapy, and pharmacological consultation. In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Resynchronization Therapy for Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patients are eligible if they undergo an ICD implantation or replacement~* They have a documented LVEF ≤ 35% measured in the previous 6 months (without major clinical subsequent event, such as heart surgery, since the LVEF measurement)~* If measured by echocardiography, the LV end-diastolic diameter must be ≥ 60 mm~* The duration of the QRS is \< 120 ms~* They are in sinus rhythm~* They cannot walk more than 400 meters during the screening 6-minute walk test (the patients must be limited by heart failure symptoms)~Exclusion Criteria:~* Patients with an indication for permanent ventricular pacing or with chronotropic insufficiency defined as follow:~  * Any condition where the treating physician believes it would not be acceptable for the patient to have his device NOT programmed with the SENSOR at ON for the duration of the study~ * Second or third degree AV block, either persistent or intermittent~ * Patients with a pacemaker or an ICD who are paced in the ventricular chamber more than 5% of the time~* Patients with LV dysfunction associated with a reversible cause such as post-partum cardiomyopathy, tachycardia induced cardiomyopathy, acute myocarditis or acute toxic cardiomyopathy (including acute alcoholic)~* Patients who had a myocardial infarction within the past 6 weeks\* defined by 2 of the 3 following conditions:~  * Prolonged chest pain~ * ECG changes suggesting of AMI~ * Cardiac enzymes elevation more than twice the local upper limit of normal)~* Patients who had cardiac surgery within the past 6 weeks\*~* Patients with moderate or severe cardiac valve stenosis (aortic, mitral, pulmonary or tricuspid)~* Patients with an inability or a limitation to walk for reasons other than heart failure symptoms (e.g., angina, intermittent claudication, severe lung condition or arthrosis)~* Patients with severe coexisting illnesses making survival \> 6 months unlikely~* Patients who are pregnant and/or nursing.~* Patients with inability or unwillingness to consent or comply with follow-up requirements~* Patients participating in another study~The 6-week period is calculated prior to the beginning of the baseline evaluation and not the implant procedure itself. This difference comes from the fact that the protocol includes a delay of 2 to 8 weeks between the implant procedure and the actual beginning of the patient's evaluation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CRT (Type: EXPERIMENTAL): None
- No CRT (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Ultrasound-guided Versus Blind Insertion of Radial Artery Catheters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All surgical intensive care unit patients at Yale New Haven Hospital in whom the indication for arterial catheterization has been established by the attending physician will be eligible for consented randomization to either the Palpation or the Ultrasound group.~Exclusion Criteria:~* The patient or his/her surrogate declines to participate or the patient lacks a radial artery into which a catheter can be place.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound radial artery catheter (Type: EXPERIMENTAL): Ultrasound guided radial artery catheterization.
- Palpation based artery catheterization (Type: ACTIVE_COMPARATOR): Blind insertion of radial artery catheterization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 2 diabetes~* Diagnosis of chronic kidney disease stage 2 or 3 with an estimated GFR of 30-89 ml/min using the four variable MDRD (Modification of Diet in Renal Disease Study Group) formula~* Presence of microalbuminuria or proteinuria less than 3.5 g/d~* Diagnosis of hyperlipidemia currently treated with a statin drug~Exclusion Criteria:~* Not meeting inclusion criteria~* HDL-C \> 40 mg/dL for men, \> 50 mg/dL for women~* TG (triglycerides) \< 150 mg/dL and \> 800 mg/dL~* Documented intolerance to Niaspan or Aspirin~* Treatment with other lipid-lowering agents (fibrates, BAS \[bile acid sequestrants\], or ezetimibe)~* Elevated transaminases (AST or ALT \>1.3 x ULN)~* Unstable type 2 diabetes (FBG \>200 mg/dL or HbA1c \>9.5%)~* Known seropositivity for Hepatitis B, C, or HIV~* Documented history of malignancy~* Age \< 18 years~* Pregnant women or nursing mothers~* Inability to give informed consent~* Start or change in statin dose \< 2 months ago

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Extended release niacin (Type: ACTIVE_COMPARATOR): Extended release niacin 1500-2000 mg daily versus placebo comparator
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Standard Total Knee Arthroplasty Using Platelet Rich Plasma (PRP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is a male or female who is undergoing primary unilateral surgery or the first surgery of a staged bilateral total knee replacement where the second stage will be at least 6 weeks later~* Patient agrees to be blinded to their treatment group assignment~* Patient is willing and able to return for follow-up over at least a six (6) month post-operative period although longer follow-up may be desired~* Patient agrees to participate by signing an IRB approved Informed Consent Form~Exclusion Criteria:~* Patient will have a staged bilateral total knee replacement with the second stage to be performed less than 6 weeks after the first stage surgery PRP in~* Patient has had previous surgery on the operative knee that will necessitate the removal of existing hardware (e.g. previous osteotomy)~* Patient has a known adverse reaction or sensitivity to bovine (cow) thrombin (used as part of the platelet rich plasma system) or other bovine-derived products~* Patient has hemoglobin \< 12.0 (males), \< 11.0 (females)~* Patient has a clinically significant anxiety disorder~* Patient is on therapeutic anticoagulation medication and has an INR \> 1.3~* Patient has a severe bleeding disorder~* Patient has a known addiction to drugs or alcohol, including, but not limited to: chronic daily use of narcotic medications for more than 90 days prior to surgery~* Patient is pregnant~* Patient is a prisoner~* Patient is involved in a personal litigation (e.g. Worker's Compensation) that relates to their knee surgery~* Patient is actively participating in another medical device, drug, or biologic clinical trial (active defined as having treatment within the last 30 days)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard TKA (Type: ACTIVE_COMPARATOR): Subjects in this arm will receive total knee replacement as standard of care without Platte Rich Plasma
- Standard TKA with PRP (Type: ACTIVE_COMPARATOR): Subjects in this arm will receive total knee replacement as standard of care with Platte Rich Plasma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Cycling in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Parkinson's Disease~* Hoehn and Yahr Stages II - III.~* Ages 30-80 years~* Medical Clearance~* Ability to understand and the willingness to sign a written informed consent.~Exclusion Criteria:~* MOCA: (Montreal Cognition Scale) : rating of less than 24, indicative of cognitive dysfunction~* Changes in Parkinson's medications within the two weeks prior to starting the study~* Anticipated change in Parkinson Disease medications during the course of the study~* Uncontrolled orthostasis~* Symptomatic coronary artery disease~* Fracture of lower limb within 6 months prior to study onset or significant lower limb orthopedic diagnosis that would limit cycling~* Other significant neurologic diagnoses including multiple sclerosis or vestibular disease~* Acute illness~* Physical therapy within the month prior to study entry~* Subjects already participating in a forced exercise or high intensity exercise program~* Any medical condition that the physician investigator determined would compromise safety.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Forced exercise cycling (Type: ACTIVE_COMPARATOR): Cycling exercise at approximately 90 rpm
- Self-selected pace cycling (Type: ACTIVE_COMPARATOR): Cycling at self selected rate, with same aerobic level as forced cycling group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues